Controls ventricular rate in supraventricular tachycardia including atrial fibrillation…. ANDA 214172, held by HQ Specialty Pharma. Esmolol Hydrochloride.
As of Nov 21, 2026, ANDA 214172 (Esmolol Hydrochloride), held by HQ Specialty Pharma, was first approved by FDA on Dec 2, 2022, with 1 approved supplement and 0 published complete response letters.
Esmolol Hydrochloride in Sodium Chloride Injection is a beta-adrenergic blocker indicated for the short-term treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 2, 2022 | Original application | Approved | None posted |
| Esmolol Hydrochloride1GM/100ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Esmolol Hydrochloride2GM/100ML · injectable;injection | Esmolol Hydrochloride | Rx |
| Jun 4, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Dec 2, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters